AQST - Company ID 0001398733
Aquestive Therapeutics, Inc. trades as AQST. In its fiscal 2025 annual report the company posted revenue of $44.55M, down 22.6% from the prior year and net income of -$83.78M. This page tracks Aquestive Therapeutics, Inc. through 641 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years Aquestive Therapeutics, Inc.'s revenue declined from $66.92M to $44.55M, a compound annual decline rate of 5.0%. Net profit margin compressed from -13.4% to -188.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Insider trade | 4 | 2026-05-11 |
| Insider trade | 4 | 2026-05-07 |
The largest companies sharing Aquestive Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Aquestive Therapeutics, Inc. reported revenue of $44.55M for fiscal year 2025, a decrease of 22.6% year over year.
In its latest fiscal year Aquestive Therapeutics, Inc. reported a net loss of $83.78M.